Evidence map›Paper›PMID 26423550›Full record

Observational studyThe lancet. HIV2015

Age in antiretroviral therapy programmes in South Africa: a retrospective, multicentre, observational cohort study.

Morna Cornell, Leigh F Johnson, Michael Schomaker, Frank Tanser, Mhairi Maskew, Robin Wood, Hans Prozesky, Janet Giddy, Kathryn Stinson, Matthias Egger and 3 more

Open access · greenAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in The lancet. HIV, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Impact of Efavirenz Metabolism on Loss to Care in Older HIV+ Africans.European journal of drug metabolism and pharmacokinetics · 2019
    Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Morna CornellCentre for Infectious Disease Epidemiology and Research, Cape Town, South Africa; Division of Epidemiology and Biostatistics, Cape Town, South Africa. Electronic address: morna.cornell@uct.ac.za.
Leigh F JohnsonCentre for Infectious Disease Epidemiology and Research, Cape Town, South Africa.
Michael SchomakerCentre for Infectious Disease Epidemiology and Research, Cape Town, South Africa.
Frank TanserFaculty of Health Sciences, University of Cape Town, Cape Town, South Africa; Wellcome Trust Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Mtubatuba, South Africa.
Mhairi MaskewHealth Economics and Epidemiology Research Office, Wits Health Consortium, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Robin WoodSchool of Public Health and Family Medicine, Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, Cape Town, South Africa.
Hans ProzeskyDivision of Infectious Diseases, Department of Medicine, University of Stellenbosch and Tygerberg Academic Hospital, Tygerberg, Cape Town, South Africa.
Janet GiddyMcCord Hospital, Durban, South Africa.
Kathryn StinsonCentre for Infectious Disease Epidemiology and Research, Cape Town, South Africa; Médecins Sans Frontières, Khayelitsha, Cape Town, South Africa.
Matthias EggerCentre for Infectious Disease Epidemiology and Research, Cape Town, South Africa; Division of International and Environmental Health, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Andrew BoulleCentre for Infectious Disease Epidemiology and Research, Cape Town, South Africa.
Landon MyerCentre for Infectious Disease Epidemiology and Research, Cape Town, South Africa; Division of Epidemiology and Biostatistics, Cape Town, South Africa.
International Epidemiologic Databases to Evaluate AIDS-Southern Africa Collaboration
Wellcome Centre for Infectious Diseases Research in Africa · ZADesmond Tutu HIV Foundation · ZAMcCord Hospital · ZAStellenbosch University · ZAUniversity of Cape Town · ZAUniversity of the Witwatersrand · ZA

Funding

Observational Antiretroviral Studies In Southern Africa (OASIS) CollaborationU01AI069924 · NIAID · UNIVERSITAT BERN · PI Cleophas Chimbetete, Mary-Ann Davies · 2006 to 2026
$55.9M
NIAID NIH HHS U01 AI069924NIAID NIH HHS U01AI069924Wellcome Trust 097410
6 · The paper itself

Abstract

backgroundAs access to antiretroviral therapy (ART) expands, increasing numbers of older patients will start treatment and need specialised long-term care. However, the effect of age in ART programmes in resource-constrained settings is poorly understood. The HIV epidemic is ageing rapidly and South Africa has one of the highest HIV population prevalences worldwide. We explored the effect of age on mortality of patients on ART in South Africa and whether this effect is mediated by baseline immunological status.

methodsIn this retrospective cohort analysis, we studied HIV-positive patients aged 16-80 years who started ART for the first time in six large South African cohorts of the International Epidemiologic Databases to Evaluate AIDS-Southern Africa collaboration, in KwaZulu-Natal, Gauteng, and Western Cape (two primary care clinics, three hospitals, and a large rural cohort). The primary outcome was mortality. We ascertained patients' vital status through linkage to the National Population Register. We used inverse probability weighting to correct mortality for loss to follow-up. We estimated mortality using Cox's proportional hazards and competing risks regression. We tested the interaction between baseline CD4 cell count and age.

findingsBetween Jan 1, 2004, and Dec 31, 2013, 84,078 eligible adults started ART. Of these, we followed up 83,566 patients for 174,640 patient-years. 8% (1817 of 23,258) of patients aged 16-29 years died compared with 19% (93 of 492) of patients aged 65 years or older. The age adjusted mortality hazard ratio was 2·52 (95% CI 2·01-3·17) for people aged 65 years or older compared with those 16-29 years of age. In patients starting ART with a CD4 count of less than 50 cells per μL, the adjusted mortality hazard ratio was 2·52 (2·04-3·11) for people aged 50 years or older compared with those 16-39 years old. Mortality was highest in patients with CD4 counts of less than 50 cells per μL, and 15% (1103 of 7295) of all patients aged 50 years or older starting ART were in this group. The proportion of patients aged 50 years or older enrolling in ART increased with successive years, from 6% (290 of 4999) in 2004 to 10% (961 of 9657) in 2012-13, comprising 9% of total enrolment (7295 of 83 566). At the end of the study, 6304 (14%) of 44,909 patients still alive and in care were aged 50 years or older.

interpretationHealth services need reorientation towards HIV diagnosis and starting of ART in older individuals. Policies are needed for long-term care of older people with HIV.

fundingNational Institutes of Health (National Institute of Allergy and Infectious Diseases), US Agency for International Development, and South African Centre for Epidemiological Modelling and Analysis.

Indexed as

Program DevelopmentPublic HealthAdultAge FactorsAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountFemaleFollow-Up StudiesHIV InfectionsHumansMaleNeeds AssessmentRetrospective StudiesRisk FactorsSouth AfricaAnti-HIV Agents

Identifiers

PMID26423550
PMCPMC4603282
OpenAlexW1621884382

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.